Foot-and-mouth disease virus (FMDV) causes vesicular disease of cloven-hoofed animals, with severe agricultural and economic losses. Here we present study using a sublingual (SL) route with the killed serotype Asia 1 FMDV vaccine. Guinea pigs were vaccinated using a commercially available vaccine formulation at the manufacturer’s recommended full, 1/4, and 1/16 antigen doses. Animals were challenged with homologous FMDV Asia1 strain at various times following vaccination. All control guinea pigs exhibited clinical disease, including fever, viremia, and lesions, specifically vesicle formation in feet. Animals vaccinated with the 1/16 and 1/4 doses were protected after challenge at days 7, 28, and 35 post vaccination. These data suggest that effective protection against foot-and-mouth disease can be achieved with 1/16 of the recommended vaccine dose using SL vaccination, indicating that the sublingual route is an attractive alternative for the administration of the FMDV vaccine.
References
[1]
Carrillo C, Tulman ER, Delhon G, Vagnozzi A, Rock DL (2005) Comparative genomics of foot-and-mouth disease virus. J. Virol. 79(10): 6487–504.
[2]
Grubman M, Baxt B (2004) Foot-and-mouth disease. Clin. Microbiol. Rev. 17: 465–493.
[3]
Eble PL, Weerdmeester K, van Hemert-Kluitenberg F, Dekker A (2009) Intradermal vaccination of pigs against FMD with 1/10 dose results in comparable vaccine efficacy as intramuscular vaccination with a full dose. Vaccine 27: 1272–8.
[4]
Golde WT, Pacheco JM, Duque H, Penfold B, Ferman GS (2005) Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23(50): 5775–82.
[5]
Boender GJ, van Roermund HJ, de Jong MC, Hagenaars TJ (2010) Transmission risks and control of foot-and-mouth disease in The Netherlands: spatial patterns. Epidemics. 2(1): 36–47.
[6]
Yoon SH, Lee KN, Park JH, Kim H (2011) Molecular epidemiology of foot-and-mouth disease virus serotypes A and O with emphasis on Korean isolates: temporal and spatial dynamics. Arch Virol. 156(5): 817–26.
[7]
Pacheco JM, Mason PW (2010) Evaluation of infectivity and transmission of different Asian foot-and-mouth disease viruses in swine. J Vet Sci. 11(2): 133–42.
[8]
Dory D, Rémond M, Béven V, Cariolet R, Jestin A (2009) Foot-and-Mouth Disease Virus neutralizing antibodies production induced by pcDNA3 and Sindbis virus based plasmid encoding FMDV P1–2A3C3D in swine. Antiviral Res. 83(1): 45–52.
[9]
Dory D, Rémond M, Béven V, Cariolet R, Jestin A (2009) Pseudorabies virus glycoprotein B can be used to carry foot and mouth disease antigens in DNA vaccination of pigs. Antiviral Res. 81(3): 217–25.
[10]
Rémond M, Da Costa B, Riffault S, Zientara S, Delmas B (2009) Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site. Vaccine. 27(1): 93–8.
[11]
Niborski V, Brennan F, Lane M, Torché AM, Schwartz-Cornil I (2006) Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV.Vaccine. 24(49–50): 7204–13.
[12]
Knowles NJ, Samuel AR, Davies PR, Midgley RJ, Valarcher JF (2005) Pandemic strain of foot-and-mouth disease virus serotype O. Emerg Infect Dis. 11(12): 1887–93.
[13]
Beignon AS, Brown F, Eftekhari P, Muller S, Partidos CD (2005) A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet Immunol Immunopathol. 104(3–4): 273–80.
[14]
Nobiron I, Rémond M, Kaiser C, Lebreton F, Delmas B (2005) The nucleotide sequence of foot-and-mouth disease virus O/FRA/1/2001 and comparison with its British parental strain O/UKG/35/2001. Virus Res. 108(1–2): 225–9.
[15]
Chen HT, Zhang J, Liu YS, Liu XT (2011) Rapid typing of foot-and-mouth disease serotype Asia 1 by reverse transcription loop-mediated isothermal amplification. Virol J. 8: 489.
[16]
Callahan JD, Brown F, Osorio FA, Sur JH, Long GW (2002) Use of a portable real-time reverse transcriptase-polymerase chain reaction assay for rapid detection of foot-and-mouth disease virus. J Am Vet Med Assoc 220: 1636–42.
[17]
Thompson D, Muriel P, Russell D, Osborne P, Bromley A (2001) Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech 21: 675–87.
[18]
Fevre EM, Bronsvoort BMDC, Hamilton KA, Cleaveland S (2006) Animal movements and the spread of infectious diseases. Trends Microbiol 14: 125–31.
[19]
Yang PC, Chu RM, Chung WB, Sung HT (1999) Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet Rec 145: 731–4.
[20]
Dunn CS, Donaldson AI (1997) Natural adaption to pigs of a Taiwanese isolate of foot-and-mouth disease virus. Vet Rec 141: 174–5.
[21]
Sakamoto K, Kanno T, Yamakawa M, Yoshida K, Yamazoe R (2002) Isolation of foot-and-mouth disease virus from Japanese black cattle in Miyazaki Prefecture, Japan, 2000. J Vet Med Sci 64: 91–4.
[22]
Knowles NJ, Samuel AR (2003) Molecular epidemiology of foot-and-mouth disease virus. Virus Res 91: 65–80.
[23]
Joo YS, An SH, Kim OK, Lubroth J, Sur JH (2002) Foot-and-mouth disease eradication efforts in the Republic of Korea. Can J Vet Res 66: 122–4.
[24]
Knowles NJ, Samuel AR, Davies PR, Kitching RP, Donaldson AI (2001) Outbreak of foot-and-mouth disease virus serotype O in the UK caused by a pandemic strain. Vet Rec 148: 258–9.
[25]
Pasick J (2004) Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication. Anim Health Res Rev 5(2): 257–62.
[26]
Parida S, Cox SJ, Reid SM, Hamblin P, Barnett PV (2005) The application of new techniques to the improved detection of persistently infected cattle after vaccination and contact exposure to foot-and-mouth disease. Vaccine 23: 5186–95.
